Security
Dare Bioscience, Inc. Common Stock · DARE
DARENASDAQCommon stockCurrentCIK 1401914Updated Oct 28, 2026
Name history
Cerulean Pharma Inc. · through Jul 5, 2017Tempo Pharmaceuticals Inc · through Jan 22, 2008
DARE price & chart
Loading TradingView…
NASDAQ:DARE on TradingView ↗About the company
We are a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation we advance is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, we’re working to close critical gaps in care using science that serves her needs. In March 2025, we announced an expansion of our business model to include a dual-path approach to bringing new products to market. For select proprietary formulations, we are pursuing both traditional FDA approval and earlier market access via Section 503B compounding. We believe this strategy allows us to respond to clinician and patient demand for timely access while continuing to generate the data necessary to seek FDA approval and support long-term value creation. In addition to prescription-based offerings — both FDA-approved products and compounded drugs — we intend to bring to market select consumer health products that do not require a physician’s prescription, where appropriate based on product profile and market opportunity.
In the news
Daré Bioscience to Host Second Quarter 2026 Financial Results and Company Update Conference Call and Webcast on August 13, 2026 ↗
Seeking Alpha
Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript ↗
Daré Bioscience targets Ovaprene top-line data in 2027 as it plans DARE to PLAY dispensing this quarter ↗
Daré Bioscience, Inc. (DARE) Q2 2026 Earnings Call Transcript ↗
SEC disclosures
Dare Bioscience, Inc. files 8-K: Material Event ↗
Recent filings
DEFA14A filing
DEF 14A filing
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
Regulation FD Disclosure
Items 7.01, 9.01
PRE 14A filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 30,748,574Source | 18,058,801Source | 22,370,109Source | 12,979,525Source | 23,606,239Source | 27,828,414Source | 18,618,941Source | 13,012,722Source | 32,474,563Source | 22,101,131Source | 21,282,215Source | 43,826,383Source |
| Property, Plant and Equipment, NetUSD | 1,657,255Source | 706,256Source | 1,419,796Source | 1,651,656Source | 322,283Source | 1,448,990Source | 1,484,947Source | 52,493Source | 1,558,890Source | 1,335,732Source | 655,975Source | 64,908Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 23,075,261Source | 11,232,609Source | 12,617,594Source | 5,035,006Source | 16,414,992Source | 18,519,784Source | 10,329,967Source | 3,630,603Source | 24,711,356Source | 15,698,174Source | 10,476,056Source | 34,669,605Source |
| Assets, CurrentUSD | 25,004,180Source | 14,946,271Source | 16,686,163Source | 6,602,417Source | 20,829,455Source | 21,659,137Source | 11,822,549Source | 9,982,561Source | 27,063,879Source | 18,447,863Source | 17,543,539Source | 43,038,753Source |
| Operating Lease, Right-of-Use AssetUSD | 824,693Source | 1,327,833Source | 837,596Source | 955,651Source | 1,445,823Source | 969,256Source | 1,083,036Source | 1,560,706Source | 1,097,580Source | 1,206,942Source | 1,319,630Source | 458,000Source |
| Other Assets, NoncurrentUSD | 1,018,373Source | 533,942Source | 2,554,166Source | 1,069,902Source | 528,571Source | 2,442,450Source | 1,078,527Source | 654,530Source | 1,009,439Source | 1,098,567Source | 599,594Source | 722,722Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 27,890,671Source | 19,543,284Source | 22,930,209Source | 25,712,785Source | 20,934,733Source | 27,093,963Source | 28,182,642Source | 24,012,132Source | 29,631,929Source | 28,113,220Source | 26,329,855Source | 32,714,273Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 759Source | 0Source | 0Source | 656Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 1,393Source | 854Source | 1,517Source | 903Source | 854Source | 1,456Source | 885Source | 10,058Source | 1,450Source | 870Source | 9,997Source | 8,482Source |
| Retained Earnings (Accumulated Deficit)USD | -187,247,186Source | -169,783,232Source | -194,671,566Source | -183,684,420Source | -165,080,731Source | -191,688,793Source | -179,667,937Source | -177,991,387Source | -188,688,904Source | -175,289,630Source | -171,236,031Source | -141,074,640Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -395,966Source | -362,625Source | -374,856Source | -402,826Source | -385,560Source | -377,081Source | -415,719Source | -400,123Source | -421,623Source | -428,809Source | -360,896Source | -351,311Source |
| Stockholders' Equity Attributable to ParentUSD | 2,857,903Source | -1,484,483Source | -560,100Source | -12,733,260Source | 2,671,506Source | 734,451Source | -9,563,701Source | -10,999,410Source | 2,842,634Source | -6,012,089Source | -5,047,640Source | 11,112,110Source |
| Additional Paid in Capital, Common StockUSD | 190,499,662Source | 168,660,520Source | — | 171,353,083Source | 168,136,943Source | — | 170,519,070Source | 167,382,042Source | 191,951,711Source | 169,705,480Source | 166,539,290Source | 152,529,579Source |
| Liabilities and EquityUSD | 30,748,574Source | 18,058,801Source | 22,370,109Source | 12,979,525Source | 23,606,239Source | 27,828,414Source | 18,618,941Source | 13,012,722Source | 32,474,563Source | 22,101,131Source | 21,282,215Source | 43,826,383Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 21,216,394Source | 13,155,725Source | 16,922,620Source | 19,221,143Source | 14,589,933Source | 21,119,013Source | 21,188,074Source | 17,724,909Source | 23,685,687Source | 21,609,013Source | 20,480,436Source | 31,623,927Source |
| Operating Lease, Liability, CurrentUSD | 609,224Source | 505,824Source | 594,493Source | 588,478Source | 488,152Source | 598,556Source | 568,297Source | 470,390Source | 602,552Source | 548,638Source | 468,726Source | 398,391Source |
| Accounts Payable, CurrentUSD | 1,844,862Source | 1,048,679Source | 762,914Source | 1,762,600Source | 1,909,760Source | 1,231,086Source | 1,883,142Source | 4,040,509Source | 1,200,686Source | 1,455,832Source | 3,385,551Source | 2,027,953Source |
| Operating Lease, Liability, NoncurrentUSD | 288,566Source | 897,790Source | 273,872Source | 448,206Source | 1,036,683Source | 418,253Source | 603,295Source | 1,171,592Source | 559,365Source | 754,383Source | 935,743Source | 90,346Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 2,324,931Source | 1,850,862Source | 448,945Source | 2,523,603Source | 1,254,358Source | 529,325Source | 1,771,666Source | 1,370,465Source | 725,184Source | 3,042,918Source | 2,889,005Source | 10,894,016Source |
| Additional Paid in Capital | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
| Long-term Debt, Current Maturities | —Source | — | — | —Source | — | — | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 554,643Source | 175,642Source | 1,634,486Source | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 455,064Source | 377,357Source | 1,496,562Source | 2,203,256Source | 2,530,684Source | 2,158,511Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 120,633Source | 0Source | 12,053Source | — | — | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | — | — | -255,146Source | -1,929,717Source | 1,357,600Source | -75,132Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -5,520,644Source | -5,470,543Source | -9,885,870Source | 5,394,247Source | -38,856,654Source | -18,088,429Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | -157,331Source | -385,278Source | -573,046Source | -629,430Source | -63,069Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 157,331Source | 385,278Source | 573,046Source | 629,430Source | 63,069Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -715,470Source | 246,577Source | 19,277,144Source | 433,830Source | 15,637,120Source | 1,343,354Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -6,191,572Source | -5,368,207Source | 9,013,182Source | 5,187,119Source | -23,858,549Source | -17,004,482Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 23,375,261Source | 11,532,609Source | 12,917,594Source | 5,335,006Source | 18,819,784Source | 10,629,967Source | 25,011,356Source | 15,998,174Source | 10,811,056Source | 34,669,605Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 44,542Source | 13,090Source | 7,186Source | -67,913Source | -9,585Source | -196,338Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | 286,602Source | 359,018Source | 455,064Source | 377,357Source | 1,496,562Source | 2,203,256Source | 2,530,684Source | 2,158,511Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 162,000Source | 42,325Source | 38,363Source | 24,202Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | 0Source | 0Source | -600,000Source | — | — |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 46,477Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| General and Administrative ExpenseUSD | — | — | 2,499,242Source | 2,041,268Source | — | 2,377,866Source | — | 2,309,164Source | — | 9,156,061Source | 12,109,691Source | 11,243,271Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,562,766Source | -4,702,501Source | -2,982,773Source | -4,016,483Source | -2,999,889Source | -4,378,307Source | -13,399,274Source | -4,053,599Source | -30,161,391Source | -30,947,738Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | -13,399,274Source | -4,053,599Source | -30,161,391Source | -30,947,738Source |
| Operating ExpensesUSD | — | — | 3,674,410Source | 4,723,040Source | 2,835,637Source | 3,806,628Source | 2,909,028Source | 4,606,545Source | 14,286,728Source | 23,461,269Source | 33,747,765Source | 41,385,488Source |
| Other Nonoperating Income (Expense)USD | — | — | 109,382Source | -21,152Source | -14,793Source | -188,683Source | -991Source | 202,811Source | -153,060Source | -981,490Source | 778,489Source | 437,750Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | 28,500Source | 0Source | 321,686Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 94,887Source | 436,248Source | 20,930,126Source | — | — | 1,300,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 124,604Source |
| Amortization of Debt Issuance Costs | — | — | — | — | — | — | — | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 2,262Source | 41,691Source | 187,546Source | — | 152,455Source | 25,427Source | 1,030,193Source | 9,784Source | 2,807,885Source | 10,000,000Source |
| Cost of Goods and Services Sold | — | — | — | — | —Source | —Source | —Source | —Source | —Source | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | — | — | 2,593,671Source | 2,377,866Source | 2,248,566Source | 2,309,164Source | 8,763,376Source | — | — | — |
| Operating Income (Loss)USD | — | — | -3,672,148Source | -4,681,349Source | -2,967,980Source | -3,827,800Source | -2,998,898Source | -4,581,118Source | -13,552,334Source | -23,451,485Source | -30,939,880Source | -31,385,488Source |
| Other Nonoperating Income (Expense)USD | — | — | 109,382Source | -21,152Source | -14,793Source | -188,683Source | -991Source | 202,811Source | -153,060Source | -981,490Source | 778,489Source | 437,750Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -13,541,000Source | -4,052,000Source | -30,159,000Source | -30,948,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,562,766Source | -4,702,501Source | -2,982,773Source | -4,016,483Source | -2,999,889Source | -4,378,307Source | -13,399,274Source | -4,053,599Source | -30,161,391Source | -30,947,738Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.28Source | -0.55Source | -0.2Source | -0.45Source | -0.21Source | -0.5Source | -1.2Source | -0.48Source | -0.35Source | -0.37Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.28Source | -0.55Source | -0.2Source | -0.45Source | -0.21Source | -0.5Source | -1.2Source | -0.48Source | -0.35Source | -0.37Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 12,755,112Source | 8,534,433Source | 14,889,832Source | 8,871,155Source | 14,522,835Source | 8,759,053Source | 11,178,752Source | 8,497,459Source | 87,303,701Source | 84,571,805Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 12,755,112Source | 8,534,433Source | 14,889,832Source | 8,871,155Source | 14,522,835Source | 8,759,053Source | 11,178,752Source | 8,497,459Source | 87,303,701Source | 84,571,805Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 2,499,242Source | 2,041,268Source | — | 2,377,866Source | — | 2,309,164Source | — | 9,156,061Source | 12,109,691Source | 11,243,271Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -13,321,000Source | -3,822,000Source | -29,099,000Source | -28,391,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | -13,399,274Source | -4,053,599Source | -30,161,391Source | -30,947,738Source |
| Operating ExpensesUSD | — | — | 3,674,410Source | 4,723,040Source | 2,835,637Source | 3,806,628Source | 2,909,028Source | 4,606,545Source | 14,286,728Source | 23,461,269Source | 33,747,765Source | 41,385,488Source |
| Research and Development ExpenseUSD | — | — | 1,175,168Source | 2,681,772Source | 241,966Source | 1,428,762Source | 660,462Source | 2,297,381Source | 5,523,352Source | 14,205,208Source | 21,538,074Source | 30,042,217Source |
Offerings
Registration 333-298585
Filing attachments
ex107.htm · S-1 · 2026-08-26
Calculation of Filing Fee Tables S-1 Dare Bioscience, Inc. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offerin…
Read attachment ↗ex4-1.htm · 8-K · 2026-08-17
EX-4.1 2 ex4-1.htm EX-4.1 Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT DarÉ BIOSCIENCE, INC. Warrant Shares: [____] Initial Exercise Date: [____], 2026 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (this “ Warrant ”) certifies that, for value received, _____________ or its assigns (the “ Holder ”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “ Initial …
Read attachment ↗ex4-2.htm · 8-K · 2026-08-17
EX-4.2 3 ex4-2.htm EX-4.2 Exhibit 4.2 EXHIBIT A NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN…
Read attachment ↗ex4-3.htm · 8-K · 2026-08-17
EX-4.3 4 ex4-3.htm EX-4.3 Exhibit 4.3 EXHIBIT A NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN…
Read attachment ↗